The extracellular matrix (ECM) is one of the major components of tumors that plays multiple
crucial roles, including mechanical support, modulation of the microenvironment, and a …

Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

N 4-Acetylcytidine (ac4C) has been found to affect a variety of cellular and biological
processes. For a mechanistic understanding of the roles of ac4C in biology and disease, we …

Mantle cell lymphoma (MCL) is an aggressive malignancy that is characterized by poor
prognosis. Large-scale pharmacological profiling across more than 100 hematological cell …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

The high complete remission rate with first-line combined fludarabine, cyclophosphamide,
and rituximab (FCR) begs the question of the value of minimal residual disease (MRD) …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Nanotechnology has become a powerful approach to improve the way we diagnose and
treat cancer. In particular, nanoparticles (NPs) possess unique features for enhanced …

Abstract On October 26, 2012, the US Food and Drug Administration (FDA) granted
accelerated approval to omacetaxine mepesuccinate (Synribo; Teva Pharmaceuticals USA …

The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent
in cancer care. Approximately 25–30% of the oncology drug pipeline involves oral agents …